...
首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >Botulinum toxin injections for the treatment of hemifacial spasm over 16 years
【24h】

Botulinum toxin injections for the treatment of hemifacial spasm over 16 years

机译:Botulinum毒素注射为16年来治疗半发性痉挛

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to investigate the efficacy and side effects of botulinum toxin (BTX) in the treatment of hemifacial spasm (HFS). We also focused on the divergence between different injection techniques and commercial forms. We retrospectively evaluated 470 sessions of BTX injections administered to 68 patients with HFS. The initial time of improvement, duration and degree of improvement, and frequency and duration of adverse effects were analysed. Pretarsal and preseptal injections and Botox (Allergan, Irvine, CA, USA) and Dysport (Ipsen Biopharmaceuticals, Paris, France) brands were compared in terms of efficacy and side effects, accompanied by a review of papers which reported BTX treatment of HFS. An average of 34.5 units was used per patient. The first improvement was felt after 8 days and lasted for 14.8 weeks. Patients experienced a 73.7% improvement. In 79.7% of injections, no adverse effect was reported, in 4.9% erythema, ecchymosis, and swelling in the injection area, in 3.6% facial asymmetry, in 3.4% ptosis, in 3.2% diplopia, and in 2.3% difficulty of eye closure was detected. Patients reported 75% improvement on average after 314 sessions of pretarsal injections and 72.7% improvement after 156 sessions of preseptal injections (p = 0.001). The efficacy and side effects of Botox and Dysport were similar. BTX is an effective and safe treatment option for HFS. No difference was determined between Botox and Dysport, and pretarsal injection is better than preseptal injection regarding the reported degree of improvement.
机译:本研究旨在探讨肉毒毒素(BTX)治疗面肌痉挛(HFS)的疗效和副作用。我们还关注了不同注射技术和商业形式之间的差异。我们回顾性评估了68例HFS患者470次BTX注射。分析初始改善时间、持续时间和改善程度,以及不良反应的频率和持续时间。在疗效和副作用方面,对肛前和肛前注射以及肉毒杆菌素(美国加利福尼亚州欧文市艾尔根)和Dysport(法国巴黎益生生物制药公司)品牌进行了比较,并对报道BTX治疗HFS的论文进行了综述。平均每位患者使用34.5个单位。第一次改善是在8天后感觉到的,持续了14.8周。患者有73.7%的改善。在79.7%的注射中,未报告任何不良反应,4.9%的注射部位出现红斑、瘀斑和肿胀,3.6%的面部不对称,3.4%的上睑下垂,3.2%的复视,以及2.3%的闭眼困难。患者报告称,314次肛前注射后平均改善75%,156次肛前注射后平均改善72.7%(p=0.001)。肉毒杆菌素和运动障碍的疗效和副作用相似。BTX是HFS有效且安全的治疗方案。肉毒杆菌素和呼吸困难之间没有差异,而且就报告的改善程度而言,肛前注射优于肛前注射。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号